Showing results (361-370 of 391) with videos related to
Sort By:
Pageof 40
Journal of Medicinal Chemistry|November 2, 2011
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)Sean T Murphy, Gordon Alton, Simon Bailey, et al.Ebiomedicine|January 7, 2024
Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groupsSarah Kohe, Christopher Bennett, Florence Burté, et al.Acta Neuropathologica Communications|June 2, 2016
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic studyDonato Iacovazzo, Richard Caswell, Benjamin Bunce, et al.The Lancet. Child & Adolescent Health|May 18, 2026
Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort studyStacey Richardson, Debbie Hicks, Melissa Gough, et al.Eclinicalmedicine|July 1, 2026
Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort studyStacey Richardson, Debbie Hicks, Melissa Gough, et al.Neuro-Oncology|July 17, 2021
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapseStacey Richardson, Rebecca M Hill, Christopher Kui, et al.Neuro-Oncology|September 27, 2024
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtypeMaura Massimino, Francesco Barretta, Chiara Dossena, et al.Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.Cancer Cell|December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseRebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.Journal of Medicinal Chemistry|May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutationsTed W Johnson, Paul F Richardson, Simon Bailey, et al.Pageof 40